These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 14534900

  • 1. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Drummond MW, Holyoake TL.
    Cancer; 2003 Oct 15; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
    [No Abstract] [Full Text] [Related]

  • 2. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J.
    Cancer; 2003 May 01; 97(9):2225-8. PubMed ID: 12712475
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, Díaz-Mediavilla J, Sierra J.
    Haematologica; 2003 Nov 01; 88(11):1213-20. PubMed ID: 14607749
    [Abstract] [Full Text] [Related]

  • 4. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 5. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 6. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B, Oliveira AC, Boqué C, Domingo A, Alonso E, Solé F.
    Haematologica; 2005 Apr 01; 90(4):556-8. PubMed ID: 15820956
    [Abstract] [Full Text] [Related]

  • 7. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J.
    Cancer; 2003 Nov 01; 98(9):1905-11. PubMed ID: 14584073
    [Abstract] [Full Text] [Related]

  • 8. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N, Bossone G, Della Longa G, Di Cocco B.
    Minerva Med; 2003 Apr 01; 94(2):71-6. PubMed ID: 12858155
    [Abstract] [Full Text] [Related]

  • 9. Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.
    Connor RF, Hurd D, Pettenati MJ, Koty P, Molnár I.
    Leuk Res; 2006 Oct 01; 30(10):1249-52. PubMed ID: 16580068
    [Abstract] [Full Text] [Related]

  • 10. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.
    Cancer; 2008 Feb 15; 112(4):837-45. PubMed ID: 18085610
    [Abstract] [Full Text] [Related]

  • 11. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
    Cariani E, Capucci M, Micheletti M, Spalenza F, Zanella I, Albertini A, Rossi G.
    Ann Hematol; 2003 Jun 15; 82(6):333-5. PubMed ID: 12734675
    [Abstract] [Full Text] [Related]

  • 12. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 13. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 14. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
    Richardson MW, Grewal SS.
    Pediatr Blood Cancer; 2008 Jan 15; 50(1):186. PubMed ID: 17455313
    [No Abstract] [Full Text] [Related]

  • 15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 16. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
    Marcucci G, Perrotti D, Caligiuri MA.
    Clin Cancer Res; 2003 Apr 15; 9(4):1248-52. PubMed ID: 12684391
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krecak-Gverić V, Kovacević J, Serventi-Seiwerth R, Mrsić-Davidović S, Zadro R, Boban D.
    Lijec Vjesn; 2003 Apr 15; 125(7-8):176-9. PubMed ID: 14692090
    [Abstract] [Full Text] [Related]

  • 18. Imatinib and chronic-phase leukemias.
    Boros LG, Lee WN, Cascante M.
    N Engl J Med; 2002 Jul 04; 347(1):67-8. PubMed ID: 12097546
    [No Abstract] [Full Text] [Related]

  • 19. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.
    Clin Cancer Res; 2007 Oct 15; 13(20):6136-43. PubMed ID: 17947479
    [Abstract] [Full Text] [Related]

  • 20. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.